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Abstract: The avian pathogen fowlpox virus (FWPV) has been successfully used as a vaccine vector in
poultry and humans, but relatively little is known about its ability to modulate host antiviral immune
responses in these hosts, which are replication-permissive and nonpermissive, respectively. FWPV is
highly resistant to avian type I interferon (IFN) and able to completely block the host IFN-response.
Microarray screening of host IFN-regulated gene expression in cells infected with 59 di↵erent,
nonessential FWPV gene knockout mutants revealed that FPV184 confers immunomodulatory
capacity. We report that the FPV184-knockout virus (FWPVD184) induces the cellular IFN response as
early as 2 h postinfection. The wild-type, uninduced phenotype can be rescued by transient expression
of FPV184 in FWPVD184-infected cells. Ectopic expression of FPV184 inhibited polyI:C activation
of the chicken IFN-  promoter and IFN-↵ activation of the chicken Mx1 promoter. Confocal and
correlative super-resolution light and electron microscopy demonstrated that FPV184 has a functional
nuclear localisation signal domain and is packaged in the lateral bodies of the virions. Taken together,
these results provide a paradigm for a late poxvirus structural protein packaged in the lateral bodies,
capable of suppressing IFN induction early during the next round of infection.
Keywords: fowlpox virus; interferon; lateral bodies; nuclear localisation signal; microarrays
1. Introduction
Poxviruses are large, enveloped, double-stranded DNA viruses capable of causing disease in
mammals, birds and insects. Binding and entry of poxviruses into vertebrate cells is an e cient
process for a wide range of cell types, irrespective of the host species, with any host range restriction
occurring after viral entry [1]. The complex replication cycles of poxviruses take place exclusively in
the cytoplasm, although it has long been suggested that poxviruses must interact with host nuclei for
productive infection [2–6]. Perhaps the best-studied antiviral host restriction mechanism is interferon
(IFN)-mediated, against which almost all viruses have evolved defence mechanisms [7,8]. Some of the
first viral anti-IFN defence mechanisms were elucidated using vaccinia virus (VACV), which expresses
multiple, often redundant inhibitors of IFN induction, JAK/STAT signalling and IFN-stimulated genes
(ISGs), as well as IFN-receptor antagonists and mimics of IFN ligands [7–12].
These potent immunomodulators are produced mainly during the early phase of VACV gene
expression. However, poxviruses have strategies in place to prevent or evade immediate–early host
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innate responses induced as a consequence of the virus binding and fusing with the cell membrane.
Poxviruses have proteinaceous substructures, termed lateral bodies (LBs), outside the core but within
the mature virion’s membrane. These are analogous to herpesvirus tegument proteins, some of which
perform immunomodulatory functions early during infection [13–16].
Schmidt et al. [17] reported that VACV packages the conserved H1 phosphatase (also known as
VH1) within LBs. When VH1 is released from LBs into the cytoplasm of the host cell following membrane
fusion, it acts to block IFN- -mediated STAT-dependent signalling prior to gene expression [18].
Whether additional LB-resident viral immune modulators, capable of blocking other parts or the IFN
system, are packaged in the LB of VACV or other poxviruses remain to be determined.
Relative to our understanding of the immunomodulation mediated by mammalian poxviruses,
our knowledge of the strategies deployed by avipoxviruses to disarm the interferon response remains
rudimentary. A prototypic member of the avipoxviruses, the fowlpox virus (FWPV) is the causal agent
of a widespread, enzootic disease of domestic chickens and other gallinaceous birds [19]. Like VACV,
it has been developed for use as a recombinant vector for the expression of antigens from several
avian and human pathogens in both poultry and humans [19,20]. The commercial FWPV recombinant
vaccine (TROVAC-H5) expressing the hemagglutinin gene of H5N8 isolate A/turkey/Ireland/1378/83
has become the most extensively used live recombinant virus used, with almost 2 billion doses used
against highly pathogenic influenza H5N2 [20].
In common with the other poxviruses, FWPV has developed strategies to disarm the host
IFN-response and has been found to e ciently block the pI:C-mediated induction of the IFN- promoter
and the IFN-stimulated induction of ISGs in chicken cells [20]. Studies of FWPV immunomodulators
have been complicated by the fact that only 110 (42%) of FWPV genes share significant similarity to
those in other poxviruses [21]. To identify the innate immunomodulatory factors encoded by FWPV,
we previously conducted two broad-scale pan-genome analyses of FP9, a highly attenuated strain used
as a vaccine vector in both poultry and mammals [21,22]. In the first study, we identified FPV012 as a
modulator of IFN induction by screening a knockout library of 65 nonessential FP9 genes [20,23]. In the
second study, using a gain-of-function approach, in which 4–8 kbp fragments of FP9 were introduced
into modified vaccinia Ankara (MVA), we found that FPV014 contributes to increased resistance to
exogenous recombinant chicken IFN-↵ [24].
In this report, we use our existing FP9 knockout library [20] to screen infected primary chicken
embryo fibroblasts (CEFs) for FWPV genes that modulate the induction of interferon-regulated
genes (IRG)s. Using this approach, we identified FPV184 as a third FWPV immunomodulatory
protein blocking the induction of innate immune responses. Intriguingly, unlike the FWPV
immunomodulators FPV012 and FPV014 (which are both early viral proteins), FPV184 was found to
be a late, structural protein with a functional nuclear localisation signal. Consistent with its ability to
modulate ISG responses soon after infection and long before de novo production, we show that FPV184
is packaged into FWPV particles where it resides in LBs. These results suggest that the packaging of
late immunomodulatory proteins and their subsequent delivery into the nucleus of newly infected
cells serve as an immediate–early innate immune evasion strategy.
2. Experimental Section
2.1. Cells and Viruses
Freshly isolated chicken embryo fibroblasts (CEFs) were provided by the former Institute for
Animal Health, Compton, Berks, UK (now the Pirbright Institute, UK). Primary CEFs derived
from special SPF chicken lines are normally used for propagation and titration of FWPV [19].
CEFs were cultured in 199 media (Gibco®, Invitrogen, Carlsbad, CA, USA), supplemented with
8% heat-inactivated newborn calf serum (NBCS; Gibco®, Invitrogen), 10% tryptose phosphate broth
(Sigma-Aldrich, St. Louis, MO, USA), 2% nystatin (Sigma-Aldrich) and 0.1% penicillin–streptomycin
(Gibco®, Invitrogen). DF-1 is a CEF-derived, spontaneously immortalised cell line, which, unlike CEFs,
Biomedicines 2020, 8, 634 3 of 21
exhibits high transfection e ciency and, at the same time, supports satisfactory propagation of
FWPV [25]. HEK293T cells are immortalised human embryonic kidney cells that are commonly
used in protein expression studies. DF-1 and HEK293T cells were maintained in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% fetal bovine serum (Gibco®, Invitrogen), and 0.1%
penicillin–streptomycin. All cells were grown at 37  C. The origin, propagation and titration (plaque
assays) of the FP9 virus have been described previously [21,26,27]. All transient transfections in the
study were conducted with Fugene HD transfection reagent (Promega, Southampton, UK) unless
otherwise specified. To collect the purified virus, confluent CEFs were infected with FP9 at 0.1 PFU per
cell. At 5 days p.i., the supernatant was harvested, along with remaining cells. Virus purification has
been described previously [27].
2.2. Generation of Viable FPV184-Knockout Viruses (Deletion Mutant Viruses)
Generation of FPV184 deletion mutant viruses was done using two di↵erent approaches—a
PCR-mediated knockout with a guanine–phosphoribosyltransferase (GPT) insertion in the middle of
the gene (FWPVD184; used for the microarray study) and a transient dominant deletion mutant virus
(TDdel184) [28]—to produce recombinant viruses. The resulting knockout viruses were sequenced
in the region of FPV184, paying attention to the overlap with FPV183, to check that no adventitious
mutations had been inadvertently introduced during the knockout procedure. The nearest flanking
genes to FPV184, FPV183 and FPV186 are oriented such that the termini of the genes are towards
FPV184, therefore making it unlikely that manipulation of FPV184 would disrupt their promoters.
Generation of dually tagged FPV184 was not possible as the sequences encoding the C-termini of
FPV183 and FPV184 overlap by (about) 30 bp.
2.2.1. Isolation of FPV184 Deletion Mutant Virus (FWPVD184) by PCR-Mediated Knockout
All primers used in the study are listed in Table S1. Insertional mutagenesis has been described
previously [20,23]. PCR-mediated knockout of FPV184 was carried out using three sets of primers;
FWPV DNA was used as the template for PCR with primers M2840 to M2841 and M2844 to M2845,
whilst the previously described vector pGPTNEB193rev [27] was used as the template for primers
M2842 and M2843. The resultant PCR products were combined in equimolar amounts, and a further
round of PCR was carried out using the flanking primer pair M2840 and M2845. The full-length PCR
construct was then used to transfect FP9 infected-CEFs, and the recombinant viruses were selected
using media containing mycophenolic acid (25 µg mL 1), xanthine (250 µg mL 1), and hypoxanthine
(15 µg mL 1; MXH). The virus was passaged three times in T25 flasks in the presence of MXH before
plaquing. The passaged virus was then plaque-purified once in the absence of MXH and once more in
the presence of MXH.
2.2.2. Isolation of FPV184 Deletion Mutant Virus (TDdel184) by Transient Dominant Selection
The FPV184 deletion plasmid was constructed using the previously described vector pGNR [26].
The 50 end of the FPV184 gene and 200 bp of the upstream sequence were amplified by PCR using
primer pair M2854 and M2856; the 30 end of the FPV184 gene and 200 bp of the downstream sequence
were amplified using primer pair M2857 and M2855. Following this first round of PCR, the products
were combined in equimolar amounts and a second round of PCR was carried out using the flanking
primer pair M2854 and M2855. Utilising BamHI and HindIII sites within M2854 and M2855, respectively,
the second round PCR product was digested and cloned into pGNR/BamHI/HindIII to produce
pGNRFPVD184. Deletion mutant virus (TDdel184) was isolated by the transient dominant selection
method [28], as described previously [26].
2.2.3. Confirmation of FPV184 Knockout in Deletion Mutant Viruses (FWPVD184 and TDdel184)
Each deletion mutant virus was screened by PCR with flanking primers (giving PCR products
of specific sizes for wild-type and knocked-out genes), one flanking primer and one primer internal
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to the deleted sequences (detecting only the wild-type gene) or one flanking primer and one primer
specific for the GPT gene (detecting the insertion of GPT into the wild-type gene). The primers used
are as follows: flanking primers M530 TO M1257; internal primer M2919 to M1257; PCR-mediated
deletion GPT primers M192 to M2854; transient dominant deletion GPT primers M192 to M1257.
2.2.4. Generation of Recombinant EGFP-Expressing Viruses (EGFP wt, NLS  and A19 NLS)
The FPV184 gene was amplified by PCR with the primers M2952 and M2951. The product
was digested with XmaI and SacII (within M2952 and M2951, respectively) and cloned into
the expression/transfer vector pEFgpt12S-CvectorEGFPmyc, which was derived from the vector
pEFgpt12S [29–31] that was previously cloned with the coding sequence of EGFP (enhanced green
fluorescent protein) from the pEGFP-C1 vector (Molecular Probes, Eugene, OR, USA) [29,31].
The cloning of the FPV184 gene into pEFgpt12S-CvectorEGFPmyc produced pCVecEGFP184 (EGFP
at the N-terminus). In addition, mutations were introduced into the FPV184 gene by PCR using the
following primer pairs: M2953 and M2951 for NLS ; M2956 and M2951 for VACV A19 NLS and two
more controls to assess the e↵ect of a putative phosphorylation site (PT; results not shown); primers
M2954 and M2951 for NLS /PT ; primers M2955 and M2951 for PT . All of the products were digested
with XmaI and SacII and cloned into pEFgpt12S-CvectorEGFPmyc/XmaI/SacII. Following transfection
of constructs into FP9-infected CEF, recombinant EGFP-expressing viruses (EGFP wild-type (wt),
NLS  and A19 NLS) were selected using mycophenolic acid and plaque-purified twice.
2.3. Multistep Growth Curve
Confluent CEFs were infected with the PCR-mediated (FWPVD184) and transient dominant
(Tddel184) knockout viruses of FPV184 or with the wild-type virus (FP9) at 0.01 PFU per cell.
The inoculum was removed 1 h later and replaced by fresh medium. At di↵erent times p.i.,
the extracellular medium was collected, and the cells were overlaid with 1 mL of fresh medium
and stored at  70  C. Intracellular and extracellular viruses were subjected to titer determination by
plaque assay [32]. Plaque sizes between wild-type and knockout viruses were evaluated as before.
Briefly, plaques areas were digitally enlarged and calculated in arbitrary units using ImageJ v.32
image analysis software. Scatterplots were created with GraphPad prism v.6.0 (GraphPad software.
San Diego, CA, USA).
2.4. Generation of Expression Constructs (pcDNA6FPV184V5His, pFPV184, pVACV-A19)
The FPV184 gene was amplified by PCR with M2892 and M2893. The product was digested with
HindIII and XhoI and cloned into pcDNA6V5His/HindIII/XhoI (Invitrogen) to give pcDNA6FPV184V5His
or amplified with 4279 and 4280 and digested with XhoI and SalI into pCIFLAG(N-terminus)/XhoI/SalI
to give pFPV184. VACV A19 was amplified with 4344 and 4345 and digested with XhoI and SalI into
pCIFLAG/XhoI/SalI to give pVACV-A19.
2.5. Infection of CEFs for Microarray and qPCR Analyses
Media was removed from fully confluent CEFs (in T25 flasks; Greiner Bio-one (Alphen a/d
Rijn, The Netherlands); 5.6 ⇥ 106 cells/flask) and replaced with 8 mL DMEM containing DMEM
(mock-infected), FP9 (MOI; multiplicity of infection: 5) or one of the knockout viruses (MOI: 5). After 2 h,
DMEM or virus-containing DMEM was replaced with culture media (199 media supplemented with
2% NBCS, 10% TPB, 2% nystatin and 0.1% penicillin/streptomycin) and cells were then incubated for a
further 14 h before harvesting. Mock- and virus-infected cells were harvested at 16 h postinfection and
stored at  80  C in RNALater (Sigma-Aldrich) until RNA extraction. The experiment was repeated in
triplicate for each knockout virus (for FWPVD228, virus duplicates were used) using three di↵erent
batches of CEFs.
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2.6. RNA Extraction and Processing of Samples for Microarray
RNA isolation and processing of samples and microarrays was done as previously described [25].
Total RNA was extracted from mock-, infected-, and IFN-stimulated DF-1 and CEFs using the
RNeasy kit (Qiagen, West Sussex, UK) according to the manufacturer’s instructions, as previously
described [25]. On-column DNA digestion was performed using RNase-free DNase (Qiagen) to remove
contaminating genomic DNA. RNA samples were quantified using a Nanodrop spectrophotometer
(Thermo Fisher Scientific, Waltham, MA, USA), and their quality was evaluated using a 2100 bioanalyser
(Agilent Technologies, Santa Clara, CA, USA). All RNA samples had an RNA integrity number  9.6.
RNA samples were processed for microarray using the GeneChip® 30 IVT Express Kit (A↵ymetrix,
Emeryville, CA, USA) according to the manufacturer’s instructions, as previously described [25].
Total RNA (100 ng) was used as input, and quality checks were performed using the bioanalyser
at all stages. RNA samples were processed in batches of 12, and batch mixing was used at every
stage to avoid creating experimental bias. Hybridisation of RNA to chips and scanning of arrays was
performed by the Medical Research Council’s Clinical Sciences Centre (CSC) Genomics Laboratory,
Hammersmith Hospital, London, UK, as previously described. The RNA was hybridised to GeneChip
Chicken Genome Array chips (A↵ymetrix; containing comprehensive coverage of 32,773 transcripts
corresponding to over 28,000 chicken genes) in a GeneChip hybridisation oven (A↵ymetrix), the chips
were stained and washed on a GeneChip Fluidics Station 450 (A↵ymetrix), and the arrays were scanned
in a GeneChip Scanner 3000 7G with an autoloader (A↵ymetrix).
2.7. Microarray Data Analysis
A one-way ANOVA adjusted with the Benjamini–Hochberg multiple-testing correction (false
discovery rate (FDR) of p < 0.05) was performed with Partek Genomics Suite (v6.6, Partek Inc, St Louis,
MO, USA) across all samples, as previously described [25,33]. Comparisons were conducted between
infected cells versus mock-treated cells and between infected cells with the KO viruses versus CEFs
infected with the parental FP9 strain. The analysis cut-o↵ criteria were fold change   ±1.5 and p-value
0.05. The A↵ymetrix chicken genome arrays contain probe sets for detecting transcripts from 17 avian
viruses, including FWPV, allowing confirmation of viral infection. Visualisation of gene expression
data was conducted with GeneSpring GX (v.13.1, Agilent Technologies) and GraphPad Prism (v.6.0).
Original microarray data produced in this study have been deposited according to the MIAME
guidelines in the public database ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae/; Acc. No:
E-MTAB-7276). A catalogue of 337 ISGs was created by applying a fold change >3 compared to mock
and false discovery rates (FDRs) <0.05 on previously published microarray data ([34]; ArrayExpress
accession: E-MTAB-3711 and Table S2).
2.8. Quantitative Real-Time RT PCR
Quantitative real-time RT PCR was performed on RNA samples using a two-step procedure,
as previously described [35]. RNA was first reverse-transcribed into cDNA using the QuantiTect
Reverse Transcription Kit (Qiagen) according to manufacturer’s instructions. qPCR was then conducted
on the cDNA in a 384-well plate with an ABI-7900HT Fast qPCR system (Applied Biosystems, Foster City,
CA, USA). Mesa Green qPCR MasterMix (Eurogentec, Seraing, Belgium) was added to the cDNA
(5 µL for every 2 µL of cDNA). The following amplification conditions were used: 95  C for 5 min;
40 cycles of 95  C for 15 s, 57  C for 20 s, and 72  C for 20 s; 95  C for 15 s; 60  C for 15 s; 95  C for 15 s.
Primer sequences for genes that were used in the study are shown in Table S1. The output Ct values
and dissociation curves were analysed using SDS v2.3 and RQ Manager v1.2 (Applied Biosystems).
Gene expression data were normalised against the housekeeping gene GAPDH and compared with
the mock controls using the comparative CT method (also referred to as the 2 DDCT method [36]).
All samples were loaded in triplicate.
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2.9. Confocal and Widefield Fluorescence Microscopy
Immunofluorescence labelling was carried out using CEFs seeded at 2.5 ⇥ 105 cells/well on
coverslips, incubated in 6-well plates at 37  C, 5% CO2 and infected with 0.5–1 pfu of virus for
24 h. The medium was aspirated; cells were washed 3 times (3⇥) with PBS and fixed with 4%
paraformaldehyde in PBS at room temperature (RT). Coverslips were washed 3⇥ in PBS, and cells
were permeabilised (0.5% Triton X-100 in PBS) at RT for 10 min with shaking. Following further 3⇥
PBS washing, cells were blocked (0.5% bovine serum albumin in PBS) for 1 h at RT with shaking.
Primary antibodies were applied at 1:200 in blocking solution for 1 h at RT with shaking, followed by
5⇥ 5 min PBS washing at RT. Secondary Alexa dye-conjugated antibodies (Molecular Probes) were
applied at 1:200 in blocking solution for 1 h at RT in the dark, followed by 5⇥ 5 min PBS washing.
For double-labelling experiments, a second round of incubation with primary antibody, washing and
secondary antibody was carried out. To label DNA within cells, coverslips were incubated with 1:5000
TOPRO3 (Molecular Probes) for 10 min at RT, followed by 3⇥ PBS washing. Coverslips were dipped in
SuperQ water briefly, drained and mounted on Vectorshield mounting media (Vector Labs, Burlingame,
CA, USA). Coverslips mounted with hard-set mounting media were allowed to set at 4  C overnight;
all other coverslips were sealed with nail varnish. Confocal microscopy was performed using a Leica
TCS NT confocal microscope (Leica, Heidelberg, Germany).
For widefield fluorescence microscopy, CEFs were washed 2⇥ with PBS at RT and fixed with 10%
bu↵ered formaldehyde. The images were acquired on Evos fluorescence microscope (Evos FL Imaging
System, Thermo Fisher Scientific).
2.10. Virion Fractionation
Purified particles of the recombinant virus, which has EGFP fused with FPV184, were incubated
in a reaction mixture containing 50 mM Tris-HCl, pH 7.5 and 1% (vol/vol) NP-40, with or without
50 mM dithiothreitol (DTT) for 1 h at 37  C. The insoluble and soluble materials were separated by
centrifugation at 20,000⇥ g for 30 min at 4  C.
2.11. Western Blotting
Proteins for Western blots were harvested from CEFs and DF-1 cells. Cell pellets were lysed with
CelLytic-M solution (Sigma-Aldrich) and the supernatant collected by centrifugation at 15,000⇥ g,
15 min, prior to protease inhibitor (Roche, Welwyn Garden City, UK) addition. To every 20 µL of
sample, 5 µL of 4⇥ loading bu↵er (Bio-Rad, Hemel Hempstead, UK) was added, and the samples were
heated to 60  C for 5 min. They were then separated on a 12% sodium dodecylsulfate polyacrylamide
gel, alongside a protein ladder (Chameleon Dual Colour Standards, LICOR, Cambridge, UK). Samples
(20 µg) were loaded for each well, and the gel was run at 150 V for 2 h. Protein samples fractionated by
SDS-PAGE were electroblotted onto a nitrocellulose membrane (Hybond-ECL; Amersham Biosciences,
Amersham, UK) by following standard protocols. After transfer, the membranes, blocked overnight
in 5% nonfat dry milk in PBS bu↵er, were incubated for 2 h at room temperature with one of the
following antibodies: mouse monoclonal anti-GFP (Sigma-Aldrich), mouse monoclonal anti-FLAG
(M2) (Sigma-Aldrich), rabbit monoclonal anti-tubulin (Cell Signalling Technology; Ipswich, MA, USA),
mouse polyclonal anti-chicken Mx1 (AbMart, Shanghai, China), and mouse monoclonal anti-FPV168
(GB9), anti-FPV140 (DF6) and anti-FPV191 (DE9; in PBS + 0.1% Tween-20 (Sigma-Aldrich) + 2% nonfat
dried skimmed milk) [27,37] at a dilution of 1:(1000–5000), followed by washing with PBS five times for
5 min. Secondary antibody (goat anti-rabbit horseradish peroxidase-conjugated or goat anti-rabbit or
donkey anti-mouse secondary antibodies (LICOR)) was diluted in PBS + 0.1% Tween-20 and added to
the blot. Incubation was allowed to proceed for 1 h, followed by washing with PBS five times for 5 min
each. Labelled proteins were detected by incubation with either the ECL detection reagent (Amersham
Biosciences) and exposure to Hyperfilm ECL chemiluminescence film (Amersham Biosciences) or
scanned with the Odyssey Imaging System (LICOR).
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2.12. Transfection of Cells with POLYI:C and Assay of Luciferase Reporters
Chicken fibroblast DF-1 cells were transfected in 12-well plates with either chicken Mx1 or chicken
IFN-  promoter reporters (100 ng) [38], the constitutive reporter plasmid pJATlacZ (100 ng) [39] or
cotransfected with plasmids driving the overexpression of FPV184 or FPV012 or VACV A19 or the
empty control vector. Following recovery for 24 h, cells were either left untreated or treated with
1000 IU/mL recombinant IFN-↵ and incubated for 6 h or transfected overnight with high molecular
weight polyI:C (10 µg/mL) purchased from InvivoGen (San Diego, CA, USA) using the Polyfect
transfection reagent (Qiagen). Luciferase assays were carried out, and data were normalised using
 -galactosidase measurements and expressed as relative luciferase activity. Cell lysate  -galactosidase
concentrations were measured by incubation of 10µL of cell lysate with ortho-nitrophenyl- -galactoside
(50 µL of 0.5 mg mL 1 diluted in 60 mM Na2HPO4·7H2O, 40 mM Na2H2PO4·H2O, 10 mM KCl, 1 mM
MgSO4·7H2O, 2.7 mL litre 1  -mercaptoethanol). The reaction mixture was incubated at 37  C until a
yellow colouration appeared; then, the A420 was measured using a spectrophotometer.
2.13. Correlative Super-Resolution Light and Electron Microscopy (CSRLEM)
Viruses expressing FPV184 with EGFP fused to its N-terminus were pelleted through 36% sucrose
and then band-purified on a 25% to 40% sucrose gradient, as described previously [40]. Virions were
diluted in 20 µl 1 mM Tris pH 9, placed in the centre of clean coverslips for 30 min and bound virus
was fixed with 4% EM-grade formaldehyde (TAAB). A small asymmetric scratch was made in the
middle of the coverslip using a diamond scorer to enable localisation of the super-resolution imaging
region of interest within the resin block for trimming, targeting and, subsequently, in sections during
electron imaging. The samples were permeabilised for 30 min with 1% Triton X-100 in PBS and
blocked with PBS containing 5% BSA (Sigma-Aldrich), 1% FCS for 30 min. Then, the samples were
immunostained overnight with anti-GFP nanobody (Chromotek, Martinsried, Germany), conjugated
in-house to AlexaFluor647-NHS (Invitrogen) in PBS containing 5% BSA at 4  C. Coverslips were
washed 3 times with PBS and mounted on a microscope slide with parafilm gasket in 1% (v/v)
 -mercaptoethanol (Sigma-Aldrich), 150 mM Tris, 1% glucose, 1% glycerol, 10 mM NaCl, pH 8 with
0.25 mg/mL glucose-oxidase and 20 µg/mL catalase.
Super-resolution microscopy was performed on an Elyra PS.1 inverted microscope (Zeiss, Dublin,
CA, USA) using an alpha Plan-Apochromat 100⇥/1.46 NA oil DIC M27 objective. STORM [41] images
were acquired with a 1.6⇥ tube lens on an iXon 897 EMCCD camera (Andor) with 20 ms exposure
time, 642 nm excitation at 100% laser power and a 655 nm LP filter. Fluorophore activation was
dynamically controlled with a 405 nm laser at 0–2% laser power. Images were processed in Fiji [42]
using ThunderSTORM [43]. Localisations were fitted with a maximum-likelihood estimator, and lateral
drift was corrected by cross-correlation; localisations <20 nm apart within 1 frame were merged,
and images were rendered using a Gaussian profile.
After super-resolution imaging of the region of interest, a series of phase-contrast images
using objectives with 10⇥, 20⇥, 40⇥ magnification and fluorescence images using an objective
with 100⇥ magnification were taken to map the region of interest and its localisation in relation
to the scratch. Coverslips were washed twice in PBS and fixed with 1.5% glutaraldehyde and 2%
EM-grade paraformaldehyde (TAAB) in 0.1 M sodium cacodylate for 45 min at room temperature.
The samples were treated with reduced osmium and tannic acid, dehydrated through an ethanol series,
and embedded in epon resin, as previously described [44]. After resin polymerisation, the coverslip
was removed using liquid nitrogen, revealing the positive pattern of the coverslip-scratch on the
surface of the resin block. Using the scratch mark as a reference and viral clusters from phase images
as fiducials, the region of interest that had been imaged for super-resolution imaging was identified
and targeted for serial sectioning. Sections were collected on formvar-coated slot grids, stained with
lead citrate and imaged using a transmission electron microscope (Tecnai T12, Thermo Fisher Scientific,
Waltham, MA, USA) equipped with a charge-coupled device camera (SIS Morada; Olympus, Tokyo,
Japan). EM and STORM images were registered using NanoJ [45]. It should be noted that preparation
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of samples for EM after super-resolution microscopy may move or remove individual virus particles,
which mandates careful registration and manual overlay of the images. However, the orientation and
structure of the fluorescence signal are clearly reminiscent of the lateral body structure observed in EM.
2.14. Phylogenetic Analysis
The amino acid sequences of FPV184 orthologues from each genus of chordopoxvirus were
subjected to multiple alignments using CLC Workbench 7 (CLC Bio, Qiagen, Aarhus, Denmark).
Protein sequence accession numbers for the indicated viruses are as follows: fowlpox virus (FPV184,
NP_039147), canarypox virus (CNPV258, NP_955281), VACV (A19, P68714), myxoma Virus (m109 L,
AQT34599), deerpox virus (DpV83gp120, YP_227495), sheeppox virus (SPPV_106, NP_659683),
swinepox virus (SPV108, NP_570268), Yaba monkey tumor virus (111L, NP_938366), molluscum
contagiosum virus (MC124, AQY16697), orf virus (ORF096, NP_957873), and crocodilepox virus (P4b,
YP_784314).
2.15. Statistical Analysis
To determine the significance of di↵erences between experimental groups, a Shapiro–Wilk
normality test was initially used to confirm whether the data followed a normal distribution for
parametric or nonparametric testing. Subsequently, one- or two-way ANOVA parametric analyses
were performed using the fold change scores with a Tukey’s or Dunnett’s multiple-comparisons test
depending on the application [46]. p-values were set at 0.05 (p  0.05) unless indicated otherwise.
Error bars represent the standard error of the mean (SEM). The correlation of expression values between
microarray analysis and qRT-PCR was statistically assessed by calculation of Pearson’s correlation
coe cient using the built-in function of GraphPad Prism (v.6.0).
3. Results
3.1. Identification of Immunomodulatory Signature Induced by FWPV 184
We infected CEFs (three independent batches) with 59 individual FWPV knockout mutants,
each deficient in one nonessential gene [20,23]. Gene expression was analysed at 16 h postinfection (p.i.)
using A↵ymetrix Chicken 32 K genome microarrays, which include probe sets for FWPV transcripts,
allowing confirmation of viral infection and genotype for each knockout virus. The parental FP9 strain
blocks the induction of IFN and ISGs entirely and served as a negative control. The FPV012 knockout
(FWPVD012), which induces a subset of ISGs [20], served as a positive control. All knockout viruses
were screened for their ability to induce ISGs using a set of 337 chicken ISGs, which were determined
by treating CEFs with IFN-↵ for 6 h [34] (ArrayExpress accession: E-MTAB-3711; Table S2).
FWPVD012 induced a subset of ISGs to moderate levels compared to the mock-infected control
(n= 87, FDR 0.05, fold change 1.5) and the FP9 virus (n= 98) (Figure 1a,b). We found that FWPVD184
induced a smaller subset of ISGs compared with the mock-infected control (n = 41) and the FP9 virus
(n = 5; IFIT5, Mx1, IFI6, ARHGAP8 (Rho GTPase activating protein 8), LOC418700 (LYG2 lysozyme
G-like 2); Figure 1a,b and Table S2).
To confirm these results, we used real-time quantitative PCR (qPCR) to analyse mRNA levels of the
“classical ISGs” Mx1, IFI6 and IFIT5 upon infection with the knockout viruses. Pearson’s correlation test
(Figure 1c) was performed to test for pairwise correlations between the two transcriptomic approaches.
The correlation coe cients (r) for all comparisons were over 0.97, indicating the reproducibility of the
expression analysed by microarray or qPCR.
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Figure 1. Disruption of FPV012 (a known FP9 immunomodulator gene) and FPV184-induced 
overlapping subsets of IFN-stimulated genes (ISGs). (a) Gene expression of selected ISGs (E4F1, 
ARHGAP8, BATF3, ZDHHC4, Mx1, IFI6, IFIT5, KCNJ5Z) for all knockout viruses measured by 
microarrays (fold-change relative to mock-infected chicken embryo fibroblasts (CEFs)). (b) Venn 
diagrams showing numbers of genes differentially regulated by FWPV∆012, FWPV∆184 or IFN-α in 
comparison with mock-infected (upper) or parental FP9-infected (lower) cells. The full gene datasets 
are listed in Table S2. (c) Comparison of median differential expression levels for 3 selected transcripts 
determined by microarray and qPCR analysis (Mx1, IFI6, IFIT5). Plots show log10 expression fold 
change for the selected genes for CEFs infected with all knockout FP9 mutant viruses compared to 
mock-infected CEFs. Pearson correlation coefficients (r) are shown in the lower right corner of each 
plot. 
3.2. FPV184 is Not an Essential Gene, but its Loss Does Impart a Defect in Viral Growth 
FPV184 is a small protein (88 amino acids) of predicted molecular weight (9.5 kDa). The presence 
of a late promoter, TAAATG, upstream of FPV184 suggested that it is a late-expressed gene unlike 
the other two known FWPV immunomodulators FPV012 and FPV014, which are expressed early 
during viral replication. Microarrays showed that FPV184 is indeed expressed at intermediate/late 
stages of FWPV replication (Figure S1c). To determine if FPV184 is essential for FWPV replication, 
we used two recombinant FWPV viruses containing a disrupted FPV184 gene, a PCR-mediated 
knockout virus (FWPV∆184; used in microarrays and the rest of the study) and a transient dominant 
virus (TDdel184). These deletion viruses could be isolated in culture, indicating that FPV184 is 
nonessential for growth in vitro, and both are able to induce Mx1 in CEFs (Figure 2a). However, the 
viruses had lower growth rates (approx. 0.75 log10 lower), reduced viral yield in CEFs (approx. 1–1.5 
log10 lower) and smaller plaque diameters (approx. two-thirds) compared to the parental FP9 virus 
(Figure 2b–e), indicating that loss of FPV184 imparts a growth defect on FWPV. 
Figure 1. Disruption of FPV012 (a known FP9 immunomodulator gene) and FPV184-induced
overlapping subsets of IFN-stimulated genes (ISGs). (a) Gene expression of selected ISGs (E4F1,
ARHGAP8, BATF3, ZDHHC4, Mx1, IFI6, IFIT5, KCNJ5Z) for all knockout viruses measured by
microarrays (fold-change relative to mock-infected chicken embryo fibroblasts (CEFs)). (b) Venn
diagrams showing numbers of genes di↵erentially regulated by FWPVD012, FWPVD184 or IFN-↵ in
comparison with mock-infected (upper) or parental FP9-infected (lower) cells. The full gene datasets
are listed in Table S2. (c) Comparison of median di↵erential expression levels for 3 selected transcripts
determined by microarray and qPCR analysis (Mx1, IFI6, IFIT5). Plots show log10 expression fold
change for the selected genes for CEFs infected with all knockout FP9 mutant viruses compared to
mock-infected CEFs. Pearson correlation coe cients (r) are shown in the lower right corner of each plot.
3.2. FPV184 Is Not an Essential Gene, but Its Loss Does Impart a Defect in Viral Growth
FPV184 is a small protein (88 amino acids) of predicted molecular weight (9.5 kDa). The presence
of a late promoter, TAAATG, upstream of FPV184 suggested that it is a late-expressed gene unlike the
other two known FWPV immunomodulators FPV012 and FPV014, which are expressed early duri g
viral replication. Microarrays showed that FPV184 is inde d expressed at int rmediate/late stages of
FWPV r plicatio (Figure S1c). To determine if FPV184 is essential for FWPV replication, we used
two recombinant FWPV viruses containing a disrup ed FPV184 gen , a PCR-mediated knockout virus
(FWPVD184; used in microarrays and the rest of the study) and a tran i nt dominant virus (TDdel184).
Th se dele ion viruses could be isolated in culture, indicating that FPV184 is nonessential for grow h
in vitro, and both are able to induce Mx1 in CEFs (Figure 2a). H wever, the viruses h d lower growth
rates (approx. 0.75 log10 lower), reduced viral yield in CEFs (approx. 1–1.5 log10 lower) nd smaller
plaque diameters (approx. two-thirds) compared to the parental FP9 virus ( igure 2b–e), indicating that
loss of FPV184 imparts a growth defect on FWPV.
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Figure 2. Deletion of FPV184 affects the replicative fitness of the recombinant virus. (a) Independent 
transient dominant (TDdel184) and GPT-insertion FPV184 knockout mutant (FWPV∆184) viruses 
(MOI (multiplicity of infection): 5, 1 h adsorption) induce similar mRNA levels of Mx1 at 4 h p.i. in 
CEFs compared to parental FP9 virus by qPCR. (b) Multiple-step growth analysis of FP9, FWPV∆184 
and TDdel184 viruses in CEFs (MOI: 0.01). (c) Viral yield of FP9, FWPV∆184 and TDdel184 viruses 
(in pfu/mL) following 72 h infection with an MOI of 0.1 in CEFs. (d) Images of viral plaques of FP9, 
FWPV∆184 and TDdel184 viruses in CEFs. (e) Scatterplot showing their respective size in arbitrary 
units. (a–e) Error bars indicate standard error of the mean (SEM); n = 3. One-way ANOVA with 
Dunnett’s post hoc test was used to analyse the data. ** p< 0.01, *** p< 0.001, **** p< 0.0001. 
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to FP9), and again at 14 to 16 h p.i. (2.2-fold compared with uninfected cells and 3.1-fold compared 
to FP9; Figure 3a). Immunoblot analysis at 4 and 16 h p.i. confirmed that FWPV∆184 could not 
suppress Mx1 protein expression (Figure 3b). As FPV184 is only expressed later during infection 
(Figures 3c and S1), we confirmed late protein expression by immunoblot against another late protein 
(FPV191; Figure 3b), which confirmed that no late viral protein was expressed at 4 h p.i. 
Figure 2. Deletion of FPV184 a↵ects the replicative fitness of the recombinant virus. (a) Independent
transient dominant (TDdel184) and GPT-insertion FPV184 knockout mutant (FWPVD184) viruses (MOI
(multiplicity of infection): 5, 1 h adsorption) induce similar mRNA levels of Mx1 at 4 h p.i. in CEFs
compared to parental FP9 virus by qPCR. (b) Multiple-step growth analysis of FP9, FWPVD184 and
TDdel184 viruses in CEFs (MOI: 0.01). (c) Viral yield of FP9, FWPVD184 and TDdel184 viruses (in
pfu/mL) following 72 h infection with an MOI of 0.1 in CEFs. (d) Images of viral plaques of FP9,
FWPVD184 and TDdel184 viruses in CEFs. (e) Scatterplot showing their respective size in arbitrary
units. (a–e) Error bars indicate standard error of the mean (SEM); n = 3. One-way ANOVA with
Dunnett’s post hoc test was used to analyse the data. ** p < 0.01, *** p < 0.001, **** p < 0.0001.
3.3. FPV184 Mediates Early Suppression of ISGs through LB Packaging
The expression kinetics of ISGs in CEFs infected with FWPVD184 or FP9 were monitored for
16 h p.i. using qPCR. FP9 infection reduced basal Mx1 expression by 30% throughout the course of
infection (Figure 3a shows mRNA xpr ssion of x1 infected with FP9 and FWPVD184 related to
u infected samples). Conversely, cells inf cted with FWPVD184 showed a mo est bimodal increase in
Mx1 expres ion from 2 to 5 h p.i. (2.8-fold compared with uninfected cells and 4.2-fold compared to
FP9), and again at 14 to 16 h p.i. (2.2-fold compared with uninfect d cells and 3.1-fold compared to
FP9; Figure 3 ). Immunoblot analysis at 4 and 16 h p.i. confirmed that FWPVD184 could not sup ress
Mx1 protein expression (Figure 3b). As FPV18 is only expressed later during infection (Figure 3c a d
Figure S1), we confirmed lat pr tein exp ssion by immunoblot against another late protein (FPV191;
Figure 3b), which confirmed that no late viral protein was expressed at 4 h p.i.
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Figure 3. FPV184 mediates early suppression of ISGs through lateral body (LB) packaging. (a) Kinetics 
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CEFs with FWPV∆184 and the wild-type FP9 viruses (MOI: 5, 1 h adsorption), measured by qPCR. ● 
and ■ represent replicate values for infection with FWPV∆184 or FP9 respectively. (b) Western blot 
showing protein expression of chicken Mx1, late-expressed FPV191 and anti-tubulin at 4 and 16 h p.i. 
infection of CEFs with FP9 and FWPV∆184 (MOI: 5) and treatment with IFN-α (1000 IU/mL). (c) 
Kinetics of FPV184 expression presented as scatter dot plots (means ± SEM, n = 3) following infection 
of CEFs with FWPV∆184 and wild-type FP9 viruses, measured by qRT-PCR. (d) Purified particles of 
the virus, with EGFP fused with FPV184, were treated with either NP-40 and/or dithothreitol (DTT), 
centrifuged to separate the pellet (P) from supernatant (S) fractions, then subjected to SDS/PAGE and 
Western blotting. Immunodetection was performed with anti-GFP antibody to detect GFP fusion 
protein(s) and monoclonal antibodies against FWPV structural proteins FPV140 (localised on mature 
virions’ membrane) and FPV168 (localised in the virion core) [37]. (e) Correlative super-resolution 
light and electron microscopy of purified recombinant viruses, which have EGFP fused with FPV184 
and were immunolabelled with anti-GFP nanobody. STORM images of the lateral body protein were 
registered with electron microscopy (EM) micrographs. Two representative virions are shown at 
higher magnification in upper and lower panels (i and ii). Scale bars: 300 nm. An overview is shown 
in Figure S2. (f) mRNA expression levels of Mx1 in CEFs at 4 h p.i. infected with FP9 or FWPV∆184 
using different MOIs (0.1, 1, 3, 5 and 10), measured by qPCR, and presented as scatter dot plots. (a,c,f) 
Figure 3. FPV184 mediates early suppression of ISGs through lateral body (LB) packaging. (a) Kinetics
of Mx1 mRNA expression presented as scatter dot plots (means ± SEM, n = 3) following infection of
CEFs with FWPVD184 and the wild-type FP9 viruses (MOI: 5, 1 h adsorption), measured by qPCR.
• and ⌅ represent replicate values for infectio it PVD184 or FP9 respectively. (b) Western blot
showing protein xpression of chicken late-expressed FPV191 and anti-tubulin at 4 and 16 h
p.i. infectio ith FP9 and FWPVD184 (MOI: 5) and tr a ment with IFN-↵ (1000 IU/mL).
(c) Kinetics of FPV184 expression presente as scatter ot plots (means ± SEM, n = 3) followi g infection
of CEFs with FWPVD184 and wild-type FP9 viruses, measured by qRT-PCR. (d) Purified particles of
the virus, with EGFP fused with FPV184, were treated with either NP-40 and/or dithothreitol (DTT),
centrifuged to separate the pellet (P) from supernatant (S) fractions, then subjected to SDS/PAGE and
Western blotting. Immunodetection was performed with anti-GFP antibody to detect GFP fusion
protein(s) and monoclonal antibodies against FWPV structural proteins FPV140 (localised on mature
virions’ membrane) and FPV168 (localised in the virion core) [37]. (e) Correlative super-resolution
light and electron microscopy of purified recombinant viruses, which have EGFP fused with FPV184
and w re immunolabelled with anti-GFP nanobody. STORM images of the late al body pr tein were
registered with electron microscopy (EM) micrographs. Two representative virions a e shown at higher
magnification in upper and lower panels (i and ii). Scale bars: 300 nm. An overview is shown in
Figure S2. (f) mRNA expression levels of Mx1 in CEFs at 4 h p.i. infected with FP9 or FWPVD184
using di↵erent MOIs (0.1, 1, 3, 5 and 10), measured by qPCR, and presented as scatter dot plots.
(a,c,f) Columns represent fold-change (means ± SEM, n = 3) compared to mock-infected CEFs; two-way
ANOVA with a Tukey’s posthoc test was used to analyse the data. * p < 0.05.
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This late expression of FPV184 is unusual, if not currently unique, for a nonessential poxviral gene
with early immunomodulatory function. The only known example of an immunomodulatory poxviral
protein with an early e↵ect is the essential VACV H1 phosphatase, which is packaged into poxvirus LBs
and delivered into host cells during virus entry to mediate early suppression of STAT1 signalling [17].
Thus, we asked if FPV184 is packaged into FWPV virions and, if so, where in the virions it is located.
Purified virions expressing FPV184 with EGFP fused to its N-terminus were left untreated or were
subjected to fractionation using NP-40 and/or DTT to separate viral membranes from cores and their
associated LBs [47]. Immunoblots directed against FWPV core protein FPV168 and membrane protein
FPV140 were used to validate the fractionation [37]. Immunoblots directed against EGFP indicated
that EGFP-fused FPV184 is packaged in virions (Figure 3d). In untreated and NP-40-treated virions,
very little EGFP-fused FPV184 was released from virions, suggesting that the protein is not on the
virions’ surface. Treatment with NP-40 and DTT [48] resulted in a 50/50 distribution of EGFP-fused
FPV184 between virion membrane and core/LB fractions, suggesting that FPV184 resides between the
viral membrane and the viral core.
To more accurately define the subviral localisation of FPV184, we used correlative super-resolution
light and electron microscopy (CSRLEM). Purified virions expressing FPV184 with EGFP fused to its
N-terminus were imaged using stochastic optical reconstruction microscopy (STORM), followed by
transmission electron microscopy (TEM). Images were registered to correlate the fluorescence signal
with EM structural information (Figure 3e and Figure S2). STORM images showed that FPV184 was
localised to the two distinct LB structures running the length of the virions and absent from the virus
cores. Correlation of these images with the corresponding TEM images showed that FPV184 is an LB
resident protein. Consistent with its delivery via LBs, the activation of Mx1 gene expression at 4 h p.i.
in cells infected with virions lacking FPV184 was found to be dose (MOI)-dependent (Figure 3f).
3.4. Ectopic Expression of FPV184 Inhibits polyI:C- and IFN-Stimulated Activation of Chicken IFN-  and Mx1
Promoters, Respectively
To directly assess the role of FPV184 in the absence of other immunomodulatory proteins
expressed during infection, we used a construct (pFPV184) to overexpress FPV184 in immortalised
DF-1 chicken fibroblast cells and assessed its ability to modulate the induction of the chicken IFN- 
promoter by the dsRNA analogue polyI:C (Figure 4a) or the chicken Mx1 promoter by recombinant
IFN-↵, as detected using a luciferase reporter assay (Figure 4b). Compared to the empty vector,
pFPV184 inhibited induction of the chicken IFN-  promoter and the Mx1 promoter by 44% and 22%,
respectively. Overexpression of FPV012, which was used as a positive control for these experiments,
inhibited induction by 74% and 51% for IFN-  and Mx1 promoters, respectively. Confirming its
role in ISG suppression during infection, transient expression of FPV184 in DF-1 cells infected
with FWPVD184 resulted in wild-type ISG-suppression levels (Figure 4c). Cotransfection of the
immortalised DF-1 chicken fibroblast cells with constructs expressing FPV184 and/or the other known
FWPV immunomodulators, FPV012 and FPV014, showed that there is no synergism between the three
proteins in inhibiting IFN-↵ stimulation of the Mx1 promoter (Figure S3).
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Figure 4. Ectopic expression of FPV184 elicits an immunomodulatory effect in chicken and human 
cells. Using a luciferase assay, the FLAG-tagged FPV184 protein was shown to inhibit the induction 
of both chicken IFN-β promoter (IFN-β-luc) by polyI:C (a) and, to a lesser extent, the chicken Mx1 
promoter (Mx1-luc) by IFN-α (b) in chicken DF-1 cells. Data are presented as relative luciferase 
activity. Two-way ANOVA (type of plasmid and effect of IFN-α or pI:C) with Bonferroni’s posthoc 
test was used to analyse the data (**** p < 0.0001). (c) Complementation assay measuring Mx1 
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plasmid or with the empty vector and infected with FWPV∆184 or FP9 for 4 h (MOI: 5). One-way 
ANOVA with Tukey’s posthoc test was used to analyse the data (***p < 0.001). (d) qPCR analysis of 
human IFN-β and (e) human CXCL10 mRNA levels in HEK293T cells transfected for 48 h with either 
an expression plasmid for FPV184 or VACV A19 and infected with parental FP9 or FWPV∆184 for 4 
h (MOI: 5). Error bars indicate SEM; n = 3. One-way ANOVA with Dunnett’s posthoc test was used 
to analyse the data. *** p < 0.001. (c–e) Results shown are representative of three independent 
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suggests that these proteins act as functional equivalents to suppress early immune responses upon 
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Figure 4. Ectopic expression of FPV184 elicits an immunomodulatory e↵ect in chicken and human
cells. Using a luciferase assay, the FLAG-tagged FPV184 protein was shown to inhibit the induction
of both chicken IFN-  promoter (I N- -luc) by polyI:C (a) and, to a lesser extent, the chicken Mx1
pr moter (Mx1-luc) by IFN-↵ (b) in chicken DF-1 cells. Data re presented as relative lu iferase activity.
Two-way ANOVA (type of plasmid and e↵ ct of IFN-↵ or pI:C) with Bonferroni’s postho t st was
used to analyse the data (**** p < 0.0001). (c) Compl mentation assay measuring Mx1 nduc ion by
qRT-PCR in DF-1 cells transiently transfected (48 h with either th FPV184 expression plasmid or
with the empty vector and infected with FWPVD184 or FP9 for 4 h (MOI: 5). One-way ANOVA with
Tukey’s posthoc test was used to an lyse the data (*** p < 0.001). (d) qPCR analysis of human IFN- 
and (e) human CXCL10 mRNA levels in HEK293T cells transfected for 48 h with either an expression
plas id for FPV184 or VACV A19 and infected with parental FP9 or FWPVD184 for 4 h (MOI: 5).
Error bars indicate SEM; n = 3. One-way ANOVA with Dunnett’s posthoc test was used to analyse the
data. *** p < 0.001. (c–e) Results shown are representative of three independent experiments and show
fold change in mRNA expression of genes compared to mock-transfected samples. Confirmation of
transfections with qPCR for mRNA levels of FPV184 and VACV A19 is presented in Figure S5.
3.5. Ectopic Expression of FPV184 and Its Ortholog, VACV A19, Restores the Immunomodulatory Capacity of
FWPVD184 in Human Cells
FPV184 is a well-conserved orthologue of VACV A19 (~40% amino acid identity; Figure S4),
an essential, late structural protein found in vertebrate but not insect poxviruses [49,50]. As to whether
VACV A19 could substitute FPV184, VACV A19 was overexpressed in human HEK293T cells infected
with FWPVD184 (Figure 4d,e and Figure S5). Under these conditions, expression of VACV A19
suppressed the induction of human IFN-  and CXCL10 as e ciently as FPV184, which served as
a positive control for this experiment. The ability of A19 protein to compensate for the loss of
FPV184 suggests that these proteins act as functional equivalents to suppress early immune responses
upon infection.
3.6. FPV184 Contains a Functional NLS That Is Partially Responsible for Its Immunomodulatory Activity
It has been previously reported that VACV A19 and its orthologs, including FPV184, contain three
highly conserved motifs: two CxxC motifs in the middle of the protein (amino acids 37–40 and
72–75), whose mutations resulted in a reduction in virus yield, and a basic NLS (FWPV amino acids
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9–14: KKRKKR; Figure 5a and Figure S4) at its N-terminus [50]. While A19 was shown to display
nucleo-cytoplasmic localisation during infection, mutation of the NLS had no apparent defect on virus
growth [50].
To study the cellular localisation of FPV184 during infection, a construct expressing
GFP/cMyc-tagged FPV184 under the control of an early/late synthetic poxvirus promoter was
generated [31]. Consistent with the VACV A19 data, expression of this tagged version of FPV184 in
FP9-infected CEFs showed its presence throughout the cytoplasm but was concentrated within the
nucleus (Figure 5b). A nonfused EGFP control was fairly evenly distributed throughout the cytoplasm
and nucleus. Expression of V5-His-tagged FPV184 from a eukaryotic expression vector, in the absence
of infection, showed the same distribution (Figure 5b).
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Materials and Methods section and Figure S4. (b) Representative confocal microscopy images of CEFs 
transfected for 48 h with expression plasmids containing either an EGFP tag alone (EGFP) or EGFP-
tagged FPV184 (pCVecEGFP184) and infected with FP9 for 16 h or transfected for 48 h with an 
expression plasmid containing V5-tagged FPV184 (pcDNA6FPV184V5His) but left uninfected. Scale 
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Figure 5. FPV184 NLS is functional, and nuclear localisation is needed for the protein’s
immunomodulatory ability. (a) Multiple amino acid sequence alignments of FPV184 orthologues
illustrate an NLS motif. Detailed information on sequences and full alignment can be found in the
Materials and Methods section and i r S4. (b) R presentative onfo al microscopy images of
CEFs sfected for 48 h with expression pla mids co taining either an EGFP tag alone (EGFP) or
EGFP-ta ged FPV184 (pCVecEGFP184) a d infected with FP9 for 16 h or transfected for 48 h with
an expression plas id containing V5-tagged FPV184 (pcDNA6FPV184V5His) but left uninfected.
Scale bar, 8 µm. (c) Upper panel: Schematic depicting modifications of the FPV184 N-terminal region
in the recombinant EGFP-expressing viruses (NLS is shown in red; the putative phosphorylation
sites in green). Lower panel: Widefield fluorescence micrographs of CEFs 24 h p.i. at an MOI of
1 with the recombinant EGFP-expressing viruses. Red arrows show nuclear-localised fluorescence.
(d) Relative luciferase activity in DF-1 cells after transfection with chicken Mx1–luciferase reporter
plasmid (Mx1–luc), together with expression plasmids for FPV184, FPV012, VACV A19 or FPV184
without the NLS domain (pFPV184NLS ). Data are presented as scatter dot plots. Two-way ANOVA
with Tukey’s posthoc test was used to analyse the data (** p < 0.01, **** p < 0.0001). Error bars indicate
SEM; n = 3.
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To determine whether the identified FPV184 NLS motif was responsible for this nuclear
accumulation, we transiently expressed FPV184 lacking its NLS (Figure 5c; NLS ). To determine if
the nuclear localisation signal found in FPV184 is functionally conserved with VACV A19, we also
swapped this region of FPV184 with the corresponding sequence from VACV (strain Western Reserve
(WR); NCBI Taxonomy ID 10254) A19 (KSRKKKPKTT) (Figure 5c; A19 NLS). These constructs were
used to generate FWPV recombinant viruses expressing the EGFP-tagged versions of FWPV184 as
second copies. Following infection with these viruses, EGFP wt showed di↵use cytoplasmic EGFP
staining and distinct accumulation of the EGFP signal within both the viral factory and nucleus,
while expression of the NLS  recombinant EGFP virus produced a di↵use EGFP fluorescence in both
nuclei and cytoplasms of infected cells (Figure 5c and confocal microscope analysis in Figure S6).
Infection of cells with A19 NLS resulted in nuclear localisation, although the intensity was decreased
compared to parental EGFP wt (Figure 5c and Figure S6). These results suggest that FWPV184 contains
a functional NLS that is responsible for localising a steady-state portion of the viral protein into the cell
nucleus throughout infection.
To assess the impact of the unusual FPV184 nuclear localisation on its ability to suppress
Mx1, FPV184, FPV184 NLS- and FPV184 A19 NLS were transiently expressed in DF-1 cells and an
Mx1–luciferase reporter assay was performed in the absence or presence of recombinant chicken
IFN-↵ (Figure 5d). FPV184 partially suppressed IFN-mediated induction of the chicken Mx1 promoter,
while FPV184 NLS- was reduced in its ability to suppress the promoter (Figure 5d). Consistent with its
conserved sequence, VACV A19 NLS was able to rescue suppression by FPV184 A19 NLS to the level
observed with FPV184 (Figure 5d).
4. Discussion
A common strategy to generate new or improved live recombinant poxvirus vaccines is to target
and delete immunomodulatory genes in the vector. There has been considerable study of multiple
immunomodulatory proteins of VACV [8–10,12] but, in contrast, few immunomodulators have been
reported in other poxviruses. In FWPV, two immunomodulatory proteins have been reported so
far: FPV012 and FPV014 [20,24]. Both are members of the ankyrin repeat protein superfamily (Pfam
clan CLO465), are expressed early during viral replication and are not essential for virus replication
in culture.
In a systematic, large-scale study, we interrogated the innate immune function of nonessential
FWPV genes by transcriptomic analysis of a library of knockout viruses derived from the highly
attenuated FWPV vaccine strain FP9. We identified a third immunomodulatory protein (FPV184),
which, unlike the other two immunomodulators, is not an ankyrin protein, is expressed late during
FP9 replication and encodes a very small structural protein packaged in the virions. There is a good
degree of conservation between FPV184 and its VACV orthologue A19. A19 is also expressed at the
intermediate/late stages of replication, but, unlike FPV184, it has been reported as essential for viral
replication [50], being involved in the maturation of VACV virions and in early viral transcription in
newly-infected cells, where it interacts directly with the viral RNA polymerase and other members
of the early transcription complex [49,50]. Since A19 is a late protein and has an essential role in
virion morphogenesis, A19 knockout viruses were not constructed and, thus, the potential role of A19
as an immunomodulator was not evaluated. Whilst conservation of A19 and FPV184 suggests an
important function for the latter, we were able to generate FWPV lacking FPV184 using two di↵erent
methodologies, showing that the gene is nonessential for replication in vitro, albeit with a reduced
replication rate.
Like VACV A19, FPV184 may act as an early viral transcription factor or a regulator. The two
CxxC motifs involved in the binding of the VACV orthologue to viral RNA polymerase [49,50] are well
conserved in FPV184. Although not investigated in this study, the presence of CxxC motifs is indicative
of a zinc finger motif [51,52]. The zinc-binding domains, initially identified as DNA binding motifs
in transcription factors, are now grouped into superfamilies based on their amino-acid composition.
Biomedicines 2020, 8, 634 16 of 21
A number of transcription factors have been found to bind the DNA sequence (A/T)GATA(A/G) in
the regulatory region of genes. These have been termed GATA-binding transcription factors and are
able to bind DNA via a conserved zinc-finger domain in which the zinc ion is coordinated by four
cysteine residues [53]. In VACV, early transcription factor null mutants have displayed defects in
morphogenesis [50,54,55]. We have not conducted morphological studies of the FWPVD184 virions,
e.g., using electron microscopy; consequently, a role for FPV184 in morphogenesis cannot be excluded.
It is well established that FWPV blocks the launch of the avian type I IFN response and the
induction of ISGs entirely. We recently showed that FWPV DNA is sensed by the chicken cGAS/STING
DNA-sensing pathway, but the downstream signalling response leading to type I IFN production is
e↵ectively blocked by the wild-type virus [56]. Infection of chicken macrophages with FWPVD184
resulted in IFN and ISG transcription, which was lost in cGAS and STING CRISPR knockout lines [56].
In this study, the relatively subtle induction of a subset of ISGs by FWPVD184 could be explained by the
presence of a multigenic, redundant system in FP9 to control host interferon response, as observed in
VACV and other poxviruses or by relatively mild stimuli. It is possible that the complementary e↵ects
of other FWPV immunomodulatory proteins alleviate the e↵ects caused by the absence of FPV184. For
example, FPV138 is a homologue of VACV H1, a protein-tyrosine phosphatase that resides in the LBs,
which, upon release into the cytoplasm, dampens type I IFN-induced, STAT1-mediated signalling. ISG
expression was higher in cells infected with FWPVD012 than with FPVD184, in terms of both numbers
and expression levels; there was, however, a significant overlap between the ISGs induced by both
viruses (Figure 1b). Furthermore, when FPV012 and FPV184 were transiently coexpressed in DF-1 cells,
they were not synergistic in inhibiting the pI:C-mediated induction of IFN-  (Figure S3), suggesting
they may target the same host immune pathways but at di↵erent time points during infection. FPV1840s
role may be to shut down immediate–early host immune responses and its function may be gradually
superseded by that of the early immunomodulatory proteins expressed de novo upon infection.
The putative role of FPV184 in blocking immediate–early host immune response is also supported
by our demonstration, with super-resolution microscopy and CSRLEM, that the protein is packaged
within the LB and outside the confines of the viral cores, where early viral transcription is executed.
LBs have been described as a poxvirus mechanism for the delivery of viral proteins to the cytoplasm of
cells soon after fusion of the MV membrane with cellular plasma or endosomal membranes; their release
and disaggregation are believed to depend upon reduction and proteasomal activity [17]. Parallels exist
with the herpes virus tegument, which is also located inside the virion (under the envelope but outside of
the capsid) and is known to deliver virion host e↵ector proteins into cells [17,57]. Our hypothesis is that
FWPV LBs contain additional packaged immunomodulatory factors that can act before core activation
and early gene expression to establish a favourable environment in the cytoplasm. Other proteins
found in LBs in VACV [17] include phosphoprotein F17 and oxidoreductase G4, both involved in
morphogenesis, as well as the dual-specificity phosphatase H1 discussed above (FWPV orthologues,
FPV103, FPV077 and FPV138, respectively). H1 has an immunomodulatory function by virtue of its
ability to target STAT-mediated signalling, required for IFN-mediated induction of ISG expression.
Our demonstration that FPV184 and VACV A19 are also packaged in LBs, with functional evidence that
they both have an immunomodulatory function, shows that they could complement H1, primarily by
blocking the induction of IFN but, to a lesser extent, also by blocking IFN-mediated induction of ISGs.
Another unexpected observation was that FPV184 is preferentially localised in the nuclei of
host cells. Few host nuclear proteins have been shown to play a part in the poxvirus lifecycle,
and fewer poxviral proteins (e.g., VACV C6, VACV F16) have been found to enter the nucleus during
an infection [58,59]. There is no evidence that host proteins are required either for DNA replication or
early gene transcription [60], but it is known that host proteins are necessary for VACV postreplication
transcription; intermediate transcription requires host protein VITF-2, which resides within the nucleus
of uninfected cells [61]. Although some poxviral proteins have been reported to enter the nucleus,
to date, there has been no identification of a poxvirus-encoded protein containing an identifiable
and functional NLS. Furthermore, the nuclear localisation of FPV184 was found to influence its
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immunomodulatory ability. Using a luciferase assay, we showed that a construct expressing FPV184
without the NLS only partially abrogated the ability of the protein to inhibit the IFN-mediated induction
of the Mx1 promoter (Figure 5d). Whether nuclear localisation is partially or fully required for the
immunomodulatory ability of FPV184 was unclear as, due to its small size (9.5 kDa), low levels of the
protein can enter the nucleus without an NLS via passive di↵usion. Myxoma virus encodes a protein
termed myxoma nuclear factor (MNF) [62], an ankyrin repeat-containing protein that localises to the
nucleus in the absence of an NLS and sequesters NF-B. The cowpox virus protein CrmA, even though
it is small enough to shuttle between the nucleus and the cytoplasm by passive di↵usion, requires a
leucine-rich nuclear export signal (NES) for its nuclear export [63]. It is possible that in the presence of
the active NLS, the accumulation of FPV184 in the nucleus is dependent on its lack of an NES.
Although the conserved block of lysines and arginines found at the N terminus of FPV184 is
characteristic of an NLS, it could also constitute a DNA/RNA binding domain. The possibility that
FPV184 might be a dsRNA-binding protein could explain the inhibition of polyI:C mediated-induction
of the IFN-  promoter but would not explain the inhibition of IFN-mediated induction of the Mx1
promoter we observed.
Collectively, the findings of this study indicate a late-expressed poxviral protein, packaged outside
of the viral cores, with a nonessential phenotype, a functional NLS and an immediate–early e↵ect on the
innate immune response, properties that make FPV184 resemble a herpesvirus tegument protein rather
than a typical early, immunomodulatory poxviral protein. The precise mechanism(s) and function(s)
of FPV184 are obscure. Nevertheless, these findings extend the paradigm by which poxvirus structural
proteins can block the induction of innate immune responses, immediately after infection, which might
be useful in vaccine development.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-9059/8/12/634/s1.
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upregulated genes, which were determined in the 6 comparisons, as summarised in Figure 1b. Each individual
tab shows one of the following comparisons: (a) FP9-infected versus mock-infected CEFs, (b) FWPVD012-infected
versus mock-infected CEFs, (c) FWPVD184-infected versus mock-infected cells, (d) IFN-↵-stimulated versus
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(chicken array probe: NC-002188.CDS95.S1_at) in mock-infected and infected CEFs with FP9 and knockout
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N-terminus, immunolabelled with anti-GFP nanobodies. STORM images of the FPV184 protein were registered
with EM micrographs of whole virions. Overview of two representative virions (i and ii), shown in higher
magnification in Figure 3e. Scale bar: 2 µm. Figure S3: Luciferase reporter gene assay. DF-1 cells were transfected
for 48 h with FPV012, FPV014 and/or FPV184 expression plasmids and a luciferase reporter plasmid directed by the
chicken Mx1 promoter, as well as an internal control. Cells were either treated overnight with chicken recombinant
IFN-↵ (1000 IU/mL) or left untreated. “Uninduced” corresponds to cells transfected only with the reporter plasmid.
The relative luciferase activities are shown. Figure S4: Multiple amino acid sequence alignments of FPV184
orthologues from each genus of chordopoxvirus: CNPV (canarypox virus), VACV (vaccinia virus), MYXV (myxoma
virus), DPV (deerpox virus), SPPV (sheeppox virus), SWPV (swinepox virus), YMTV (Yaba monkey tumour virus),
MOCV (molluscum contagiosum virus), ORFV (Orf virus), and CRV (crocodilepox virus). The alignment was
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Denmark). Figure S5: qPCR analysis of FPV184 or VACV A19 confirming transfections presented in Figure 4d,e.
HEK293T cells were infected with parental FP9 or FWPVD184 for 4 h (MOI: 5) and/or transfected with FPV184
or VACV A19 expression plasmids. Error bars indicate SEM; n = 3. One-way ANOVA with Dunnett’s posthoc
test was used to compare the induction of mRNA expression against that of cells transfected with the empty
vector. **** p < 0.001. Figure S6: Confocal analysis of CEFs infected with recombinant EGFP-expressing viruses,
as summarised in Figure 5c. Confocal microscopy was performed using a Leica TCS NT confocal microscope.
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